Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Vivalis Articles

Merger between Intercell and Vivalis planned to complete soon

14 May 2013

Vivalis and Intercell announce "merger of equals"

18 December 2012

Vivalis in new EB66 cell line deal with Merial

18 July 2012

Vivalis signs another EB66 out-licensing deal for MAb production

14 March 2012

Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25 January 2012

Sanofi Pasteur and Vivalis extend MAb accord

19 January 2012

Strong first-half 2011 for Vivalis, with net loss nearly halved

1 September 2011

Vivalis acquires single-cell antibody from SC World

28 April 2011

Kaketsuken initiates second trial of flu vaccine using Vivalis EB66 cell line

26 April 2011

Vivalis grants rights to EB66 cell line for human vaccine to unnamed company

15 April 2011

Sanofi-Aventis in licensing deal with Vivalis for MAb targeting infectious diseases and extends accord with Zealand for diabetes product

8 June 2010

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS